Escherichia coli antibodies in patients with inflammatory bowel disease.
about
Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importanceThe epidemiology and risk factors of inflammatory bowel diseaseAn abundance of Escherichia coli is harbored by the mucosa-associated bacterial flora of interleukin-2-deficient mice.Escherichia coli 'O' group serology of a haemolytic uraemic syndrome (HUS) epidemic.Systemic and mucosal antibodies to Klebsiella in patients with ankylosing spondylitis and Crohn's disease.The DNA Sensor AIM2 Maintains Intestinal Homeostasis via Regulation of Epithelial Antimicrobial Host Defense.Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease.The role of bacteria in the pathogenesis of inflammatory bowel diseaseIBD-what role do Proteobacteria play?Recent advances in understanding enteric pathogenic Escherichia coli.Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease.Crohn's disease and Mycobacterium avium subsp. paratuberculosis: current issues.Clinical aspects and pathophysiology of inflammatory bowel disease.Specificity of antibodies secreted by hybridomas generated from activated B cells in the mesenteric lymph nodes of patients with inflammatory bowel diseaseAbsence of complement fixing antibodies against lipopolysaccharides from Escherichia coli in a subgroup of patients with Crohn's disease.Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies.Pathogenesis of Crohn's disease: Bug or no bug.Distinct elevation of levels of anti-Caenorhabditis elegans antibody in sera of patients with inflammatory bowel diseaseSerum agglutinins to Eubacterium and Peptostreptococcus species in Crohn's and other diseases.The human microbiome and surgical disease.Systemic uptake and intestinal inflammatory effects of luminal bacterial cell wall polymers in rats with acute colonic injuryInterplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases.Agglutinins to bacteria in Crohn's disease.Insights into inflammatory bowel disease using Toxoplasma gondii as an infectious trigger.Crohn's disease and the mycobacterioses: a quarter century later. Causation or simple association?Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon?Pathogenic Role of Associated Adherent-Invasive Escherichia coli in Crohn's Disease.Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease.Afa/Dr diffusely adhering Escherichia coli infection in T84 cell monolayers induces increased neutrophil transepithelial migration, which in turn promotes cytokine-dependent upregulation of decay-accelerating factor (CD55), the receptor for Afa/Dr aInfectious agents in Crohn's disease-fact or artefact?Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease.Rises in antibody to enteric gram negative bacilli after open heart surgery: a possible mechanism for postoperative pyrexia.Crohn disease arthropathy: antigens in synovial fluid share epitopes with strains of two species of viridans streptococci.Selected bacterial antibodies in Crohn's disease and ulcerative colitis.Genetically related Escherichia coli strains associated with Crohn's disease.Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease.Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice.Mucosa-associated but not luminal Escherichia coli is augmented in Crohn's disease and ulcerative colitis.Mucosal-associated bacterial flora of the intestine in patients with Crohn's disease and in a control group.Increased incidence of faecal coliforms with in vitro adhesive and invasive properties in patients with ulcerative colitis.
P2860
Q24540422-DB7077E7-F61E-49A0-8AD6-8446A1C86C26Q26765284-83602708-1C5C-4D3B-B8AA-3CCB3F7B3CF5Q33200059-A9285625-4D3F-4EED-A4D7-5FD1339B0D04Q33333740-8EDFF280-FC9F-4721-90D4-7F353B9C1523Q33565120-FFC61A81-C456-4E14-BEEB-60C9B5BF129CQ33814705-B12594AF-9F10-48BA-8798-23A705FE1ABBQ33958858-98BDB06B-3F48-4A24-B04E-4A9AC32DA473Q34206639-95EF41FF-001C-46E9-AA7D-F39A6CE7F7C7Q34255700-A7B0109E-2029-4BDB-80A9-4C1E010E1C2BQ34375210-F8C3377B-183E-40C6-9CC8-096770B1F154Q34395670-0F9818F2-DC30-42A6-961E-3639261B48F1Q34480355-1B7A8863-4185-45ED-92D6-AFA239CBEA44Q34487217-4A8C110F-8A54-40CA-A06B-77C067EA4F33Q34528696-CC02F350-C175-4F1B-9B6A-3E0AFF16FE76Q34530193-C4592ACA-DB49-4736-B648-C4A5D5BCC961Q34786166-7672871C-1A7E-4E11-9965-410BD126A65DQ35075535-485003E5-3323-4017-9042-157B52C27318Q35923523-2BE9414E-511F-4BA1-8EAF-E7699983FEBCQ36258045-E529CAD4-9171-4ACA-BFA8-083B62AAB935Q36861745-D1D7B063-1B91-4885-B663-5699E16A9C5CQ36998318-D3F43CDF-66B7-4C61-A2C2-3E4A1E28EC54Q37163426-375A3F66-58CF-47EA-B65F-CA1C6962B175Q37909983-41FAFCA6-42DA-4F76-A9E0-3E64240F9F18Q37953824-3DCFF290-5776-4FF9-97CD-208C43C22C83Q37975540-B2DDB46C-6BFB-46F3-953D-6BF242D3F1E3Q38256340-7211B31F-5D83-48E5-B4A8-A5748BE3A288Q39124653-F2B8F383-A0BF-47CB-8EAF-AE0E19048990Q39511730-ECA45764-0F70-41E7-B4A0-5D18CA030CF0Q39741717-D33E4951-6D60-407B-BED3-2EE40283EF9DQ40320880-94C22FD8-EFBC-4171-AF5B-D5379AA34375Q40398650-9C26A1C2-3881-4EAA-B6E5-BD797C21BDDAQ40816852-3F3A466B-4C24-44C9-8F22-6BDBC29A72B2Q41479975-416EE732-7F97-4A2E-A5A1-1B9431595E94Q41591491-EEAE3247-8B18-4F6C-8254-4BF301A7C21CQ41761919-BF3C5CBB-93E1-43E4-B68A-C4C5756AD634Q41965030-25FA64DF-5CA2-4940-99D4-3235D6CFB27EQ42128973-EE7D0944-316C-45CB-8D32-C76489604C0DQ42659402-1B69F2A4-5748-4D1B-BA8C-8CB261A8B06BQ43249914-4321D090-60ED-4CE7-8955-AAC8CC1E11B8Q43255619-0789650C-2027-40B8-8E41-47BE3A7E323C
P2860
Escherichia coli antibodies in patients with inflammatory bowel disease.
description
1978 nî lūn-bûn
@nan
1978 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Escherichia coli antibodies in patients with inflammatory bowel disease.
@ast
Escherichia coli antibodies in patients with inflammatory bowel disease.
@en
Escherichia coli antibodies in patients with inflammatory bowel disease.
@nl
type
label
Escherichia coli antibodies in patients with inflammatory bowel disease.
@ast
Escherichia coli antibodies in patients with inflammatory bowel disease.
@en
Escherichia coli antibodies in patients with inflammatory bowel disease.
@nl
prefLabel
Escherichia coli antibodies in patients with inflammatory bowel disease.
@ast
Escherichia coli antibodies in patients with inflammatory bowel disease.
@en
Escherichia coli antibodies in patients with inflammatory bowel disease.
@nl
P2093
P2860
P921
P356
P1433
P1476
Escherichia coli antibodies in patients with inflammatory bowel disease.
@en
P2093
Bettelheim KA
O'Donoghue DP
Tabaqchali S
P2860
P304
P356
10.1136/GUT.19.2.108
P407
P577
1978-02-01T00:00:00Z